WSK-V305

WSK-V305 is a preclinical recombinant vaccine candidate being developed by WestVac Biopharma for the treatment of pulmonary fibrosis. As a therapeutic vaccine, it is designed to utilize recombinant protein technology to target the underlying pathological processes of lung scarring and fibrotic progression. While the specific molecular target and mechanism of action have not been publicly disclosed, WestVac Biopharma typically utilizes an insect cell (Sf9) expression platform for its recombinant protein products. The development of this candidate represents an immunotherapeutic approach to managing chronic respiratory conditions characterized by excessive connective tissue deposition.